CD47 and hepatocellular carcinoma: Our results also validate recent results observed in a hepatoma cell lines resistant to Sorafenib, where it was proposed that resistance to the drug treatment was associated with high CD47 protein levels achieved by the binding of NFKB2 subunit to the CD47 promoter upon TNF-α stimulation15.